fda ban tirzepatide Compounded Still on Market Despite fda ban on compounded tirzepatide

For patients with pre-existing osteopenia or osteoporosis, a baseline DXA may change the risk-benefit calculation of GLP-1 therapy entirely

Additionally, the appetite-suppressing effects of GLP-1 medications can partially attenuate over time as receptors adjust to sustained stimulation

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

Legumes: Lentils and beans

Armstrong MJ, Hull D, Guo K, et al

When our friend tirzepatide received its FDA approval for weight loss, and simultaneously telehealth platforms increased prescribing of GLP-1s for patients, we saw this shortage situation explode